Neesgaard, Bastian, Greenberg, Lauren, Miro, Jose M., Grabmeier-Pfistershammer, Katharina, Wandeler, Gilles, Smith, Colette, De Wit, Stephane, Wit, Ferdinand, Pelchen-Matthews, Annegret, Mussini, Cristina, Castagna, Antonella, Pradier, Christian, Monforte, Antonella D'Arminio, Vehreschild, Jorg J., Sonnerborg, Anders, Anne, Alain, V, Carr, Andrew, Bansi-Matharu, Loveleen, Lundgren, Jens D., Garges, Harmony, Rogatto, Felipe, Zangerle, Robert, Gunthard, Huldrych F., Rasmussen, Line D., Necsoi, Coca, van der Valk, Marc ORCID: 0000-0002-8290-6425, Menozzi, Marianna, Muccini, Camilla, Peters, Lars, Mocroft, Amanda and Ryom, Lene (2022). Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. Lancet HIV, 9 (7). S. E474 - 12. SAN DIEGO: ELSEVIER INC. ISSN 2352-3018

Full text not available from this repository.

Abstract

Background Although associations between older antiretroviral drug classes and cardiovascular disease in people living with HIV are well described, there is a paucity of data regarding a possible association with integrase strand-transfer inhibitors (INSTIs). We investigated whether exposure to INSTIs was associated with an increased incidence of cardiovascular disease. Methods RESPOND is a prospective, multicentre, collaboration study between 17 pre-existing European and Australian cohorts and includes more than 32000 adults living with HIV in clinical care after Jan 1,2012. Individuals were eligible for inclusion in these analyses if they were older than 18 years, had CD4 cell counts and HIV viral load measurements in the 12 months before or within 3 months after baseline (latest of cohort enrolment or Jan 1, 2012), and had no exposure to INSTIs before baseline. These individuals were subsequently followed up to the earliest of the first cardiovascular disease event (ie, myocardial infarction, stroke, or invasive cardiovascular procedure), last follow-up, or Dec 31,2019. We used multivariable negative binomial regression to assess associations between cardiovascular disease and INSTI exposure (0 months [no exposure] vs >0 to 6 months, >6 to 12 months, >12 to 24 months, >24 to 36 months, and >36 months), adjusted for cardiovascular risk factors. RESPOND is registered with ClinicalTrials.gov , NCT04090151, and is ongoing. Findings 29 340 people living with HIV were included in these analyses, of whom 7478 (25.5%) were female, 21818 (74.4%) were male, and 44 (<1%) were transgender, with a median age of 44.3 years (IQR 36.2-51-3) at baseline. As of Dec 31,2019,14 000 (47.7%) of 29340 participants had been exposed to an INSTI. During a median follow-up of 6.16 years (IQR 347-7.52; 160 252 person-years), 748 (2.5%) individuals had a cardiovascular disease event (incidence rate of 4.67 events [95% CI 4.34-5.01] per 1000 person-years of follow-up). The crude cardiovascular disease incidence rate was 4.19 events (3.83-4.57) per 1000 person-years in those with no INSTI exposure, which increased to 8.46 events (6.58-10.71) per 1000 person-years in those with more than 0 months to 6 months of exposure, and gradually decreased with increasing length of exposure, until it decreased to similar levels of no exposure at more than 24 months of exposure (4.25 events [2.89-6-04] per 1000 person-years among those with >24 to 36 months of exposure). Compared with those with no INSTI exposure, the risk of cardiovascular disease was increased in the first 24 months of INSTI exposure and thereafter decreased to levels similar to those never exposed (>0 to 6 months of exposure: adjusted incidence rate ratio of 1.85 [1.44-2-39]; >6 to 12 months of exposure: 1.19 [0.84-1-68]; >12 to 24 months of exposure: 1.46 [1.13-1-88]; >24 to 36 months of exposure: 0.89 [0.62-1-29]; and >36 months of exposure: 0.96 [0.69-1-33]; p<0-0001). Interpretation Although the potential for unmeasured confounding and channelling bias cannot fully be excluded, INSTIs initiation was associated with an early onset, excess incidence of cardiovascular disease in the first 2 years of exposure, after accounting for known cardiovascular disease risk factors. These early findings call for analyses in other large studies, and the potential underlying mechanisms explored further. Copyright (C) 2022 Elsevier Ltd. All rights reserved.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Neesgaard, BastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Greenberg, LaurenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Miro, Jose M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grabmeier-Pfistershammer, KatharinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wandeler, GillesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Smith, ColetteUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
De Wit, StephaneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wit, FerdinandUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pelchen-Matthews, AnnegretUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mussini, CristinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Castagna, AntonellaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pradier, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Monforte, Antonella D'ArminioUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vehreschild, Jorg J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sonnerborg, AndersUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Anne, Alain, VUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Carr, AndrewUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bansi-Matharu, LoveleenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lundgren, Jens D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Garges, HarmonyUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rogatto, FelipeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zangerle, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gunthard, Huldrych F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rasmussen, Line D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Necsoi, CocaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
van der Valk, MarcUNSPECIFIEDorcid.org/0000-0002-8290-6425UNSPECIFIED
Menozzi, MariannaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Muccini, CamillaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Peters, LarsUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mocroft, AmandaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ryom, LeneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-697823
DOI: 10.1016/S2352-3018(22)00094-7
Journal or Publication Title: Lancet HIV
Volume: 9
Number: 7
Page Range: S. E474 - 12
Date: 2022
Publisher: ELSEVIER INC
Place of Publication: SAN DIEGO
ISSN: 2352-3018
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
COMBINATION ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE INHIBITORS; MYOCARDIAL-INFARCTION; INITIAL TREATMENT; DOUBLE-BLIND; RISK; DOLUTEGRAVIR; PHASE-3; DRUGS; RALTEGRAVIRMultiple languages
Immunology; Infectious DiseasesMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69782

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item